Table 1.
Study Population Demographics and Baseline Characteristics
| Renal Function/Treatment Group | ||||||
|---|---|---|---|---|---|---|
| Normal Renal Function | Moderate RI | |||||
| CSL112 | CSL112 | CSL112 | CSL112 | |||
| 2 g | 6 g | Placebo | 2 g | 6 g | Placebo | |
| (n = 6) | (n = 6) | (n = 4) | (n = 6) | (n = 6) | (n = 4) | |
| Age, years | 57 ± 5 | 54 ± 10 | 56 ± 5 | 71 ± 8 | 66 ± 12 | 71 ± 5 |
| Sex, n (%) | ||||||
| Male | 5 (83.3) | 3 (50.0) | 3 (75.0) | 5 (83.3) | 4 (66.7) | 2 (50.0) |
| Female | 1 (16.7) | 3 (50.0) | 1 (25.0) | 1 (16.7) | 2 (33.3) | 2 (50.0) |
| Race, n (%) | ||||||
| White | 6 (100) | 6 (100) | 4 (100) | 6 (100) | 6 (100) | 4 (100) |
| Weight, kg | 82.0 ± 7.2 | 74.6 ± 13.4 | 77.2 ± 11.9 | 80.1 ± 11.9 | 72.8 ± 18.6 | 92.7 ± 15.5 |
| eGFR, mL/min/1.73 m2 | 99.1 ± 5.5 | 100.5 ± 6.5 | 102.7 ± 6.9 | 47.6 ± 9.1 | 51.2 ± 6.5 | 48.3 ± 8.6 |
| Plasma apoA‐I, mg/dL | 133 ± 26.3 | 150 ± 12.6 | ND | 147 ± 24.5 | 135 ± 17.8 | ND |
| Plasma PC, mg/dL | 196 ± 31.9 | 206 ± 38.0 | ND | 226 ± 26.1 | 197 ± 27.3 | ND |
| Plasma sucrose, mg/dL | BLQ | 0.7 | ND | BLQ | BLQ | ND |
Values are mean ± standard deviation unless otherwise stated.
ApoA‐I, apolipoprotein A‐I; BLQ, below the limit of quantification; eGFR, estimated glomerular filtration rate; ND, not determined; PC, phosphatidylcholine; RI, renal impairment.